Arterial Thrombosis Associated with Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Administration in Breast Cancer Patients Treated with Dose-Intensive Chemotherapy: A Report of Two Cases

References

• Goodnough L T, Saito H, Manni A, Jones P K, Pearson O H. Increased incidence of thromboembolism in stage IV breast cancer patients treated with a five-drug chemotherapy regimen: A study of 159 patients. Cancer 1984; 54: 1264–1268
   PubMed Web of Science ®Google Scholar
• Wall J G, Weiss R B, Norton L, et al. Arterial thrombosis associated with adjuvant chemotherapy for breast carcinoma: A Cancer and Leukemia Group B study. A J Med 1989; 87: 501–504
   PubMed Web of Science ®Google Scholar
• Liesche G J, Cebon J, Morstyn G. Characterization of the clinical effects after the first dose of bacterially synthesized recombinant human granulocyte-macrophage colony-stimulating factor. Blood 1989; 74(8)2634–2643
   PubMed Web of Science ®Google Scholar
• Graves E J. Detailed Diagnosis and Procedures: National Hospital Discharge Survey. 1990, Series 13, No. 113, June 1992
   Google Scholar
• Principles of Surgery, 5th ed., S I Schwartz, G T Shives, F C Spencer. McGraw-Hill, New York 1989
   Google Scholar
• Levine M N, Gent M, Hirsh J, et al. The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer. N Engl J Med 1988; 318: 404–407
   PubMed Web of Science ®Google Scholar
• Rogers J S, II, Murgo A J, Fontana J A, Raich P C. Chemotherapy for breast cancer decreases plasma protein C and protein S. J Clin Oncol 1988; 6: 276–281
   PubMed Web of Science ®Google Scholar
• Canobbio L., Fassio T, Ardizzoni A, et al. Hypercoagulable state induced by cytostatic drugs in stage II breast cancer patients. Cancer 1986; 58: 1032–1036
   PubMed Web of Science ®Google Scholar
• Antman K S, Griffin J D, Elias A, et al. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced myelosuppression. N Engl J Med 1988; 319(10)593–598
   PubMed Web of Science ®Google Scholar
• Nissen C, Tichelli A, Gratwohl A, et al. Failure of recombinant human granulocyte-macrophage colony-stimulating factor therapy in aplastic anemia patients with very severe neutropenia. Blood 1988; 72(6)2045–2047
   PubMed Web of Science ®Google Scholar
• Hoekman K, Wagstaff J, van Groeningen C J, Vermorken J B, Boven E, Pinedo H M. Effects of recombinant human granulocyte-macrophage colony-stimulating factor on myelosuppression induced by multiple cycles of high-dose chemotherapy in patients with advanced breast cancer. J Natl Cancer Inst; 1991; 83(21)1546–1553
   PubMed Web of Science ®Google Scholar
• Lockich J J, Perri J, Bothe A, et al. Cancer chemotherapy via ambulatory infusion pump. Am J Clin Oncol 1983; 6: 355–363
   PubMed Web of Science ®Google Scholar
• Lokich J J, Zipoli T E, Moore C, Sonneborn H, Paul S, Greene R. Doxorubicin/vinblastin and doxorubicin/cyclophosphamide combination chemotherapy by continuous infusion. Cancer 1986; 58: 1020–1023
   PubMed Web of Science ®Google Scholar
• Bussolino F, Ziche M, Ming Wang J, et al. In vitro and in vivo activation of endothelial cells by colony stimulating factors. J Clin Invest 1991; 87: 986–995
   PubMed Web of Science ®Google Scholar
• Sisson S D, Dinarello C A. Production of interleukin-la, interleu-kin-β and tumor necrosis factor by human mononuclear cells stimulated with granulocyte-macrophage colony-stimulating factor. Blood 1988; 72(4)1368–1374
   PubMed Web of Science ®Google Scholar
• Stehle B, Weiss C, Ho A D, Hunstein W. Serum levels of tumor necrosis factor a in patients treated with granulocyte-macrophage colony-stimulating factor. Blood 1990; 75(9)1895–1899, (letter)
   PubMed Web of Science ®Google Scholar
• de Vires E G, Willemse P H, Biesma B, Stern A C, Limburg P C, Vellegna E. Flare-up of rheumatoid arthritis during GM-CSF treatment after chemotherapy. Lancet 1991; 338: 517–518
   Web of Science ®Google Scholar
• Hazenberg B P, Van Leeuwen M S, Van Rijswijk M H, Stern A C, Vellenga E. Correction of granulocytopenia in Felty's syndrome by granulocyte-macrophage colony-stimulating factor. Simultaneous induction of interleukin-6 release and flare-up of the arthritis. Blood 1989; 74(8)2769–2773
   PubMed Web of Science ®Google Scholar
• Tijburg P N, Ryan J, Stern D M, et al. Activation of the coagulation mechanism on tumor necrosis factor-stimulated cultured endothelial cells and their extracellular matrix. J Biol Chem 1991; 266(18)12067–12074
   PubMed Web of Science ®Google Scholar
• Nawroth P P, Handley D A, Esmon C T, Stern D M. Interleukin 1 induces endothelial cell procoagulant while suppressing cell-surface anticoagulant activity. Proc Natl Acad Sci USA 1986; 83: 3460–3464
   PubMed Web of Science ®Google Scholar
• van der Poll T, Biiller H R, Cate H T, et al. Activation of coagulation after administration of tumor necrosis factor to normal subjects. N Engl J Med 1990; 322: 1622–1627
   PubMed Web of Science ®Google Scholar
• van der Poll T., Levi M, Biiller H R, et al. Fibrinolytic response to tumor necrosis factor in healthy subjects. J Exp Med 1991; 174: 729–732
   PubMed Web of Science ®Google Scholar
• Hirokawa K, Aoki N. Up-regulation of thrombomodulin in human umbilical vein endothelial cells in vitro. J Biochem 1990; 108: 839–845
   PubMed Web of Science ®Google Scholar
• Lipton A, Harvey H A, Hamilton R W. Venous thrombosis as a side effect of tamoxifen treatment. Cancer Treat Rep 1984; 68: 887–889
   PubMedGoogle Scholar
• Hagen Pt, Scholz D G, Edwards W D. Incidence and size of patent foramen ovale during the first 10 decades of life: An autopsy study of 965 normal hearts. Mayo Clin Proc 1984; 59: 17–20
   PubMed Web of Science ®Google Scholar
• Di Tullio M, Sacco R L, Gopal A, Mohr J P, Homma S. Patent foramen ovale as a risk factor for cryptogenic stroke. Ann Intern Med 1992; 117: 461–465
   PubMed Web of Science ®Google Scholar
• Lechat P H, Mas J L, Lascault G, et al. Prevalence of patent foramen ovale in patients with stroke. N Engl J Med 1988; 318: 1148–1152
   PubMed Web of Science ®Google Scholar
• de Belder M A, Tourikis L, Leech G, Camm A J. Risk of patent foramen ovale for thromboembolic events in all age groups. Am J Cardiol 1992; 69: 1316–1320
   PubMed Web of Science ®Google Scholar
• Kasper W, Geibel A, Tiede N, Just H. Patent foramen ovale in patients with haemodynamically significant pulmonary embolism. Lancet 1992; 340: 561–564
   PubMed Web of Science ®Google Scholar
• Conti J A, Scher H I. Acute arterial thrombosis after escalated-dose methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy with recombinant granulocyte colony-stimulating factor. A possible new recombinant granulocyte colony-stimulating factor toxicity. Cancer 1992; 70: 2699–2702
   PubMed Web of Science ®Google Scholar
• Gianni A M, Bregni M, Siena S, et al. Recombinant human granulocyte-macrophage colony-stimulating factor reduces hematologic toxicity and widens clinical applicability of high-dose cyclophosphamide treatment in breast cancer and non-Hodgkin's lymphoma. J Clin Oncol 1990; 8: 768–778
   PubMed Web of Science ®Google Scholar